 |
|
|
|
This page shows some of the projects that we have completed. Click on a link to
be taken to that page.
|
| | | Up to 15% of men with prostate specific antigen (PSA) levels usually considered normal have prostate cancer, which suggests that measurement of other serum biomarkers is needed to better assess risk, according to a new report. |
| | | There is a perception that subtotal hysterectomy, which is associated with little or no dissection of the bladder off the uterus and cervix, may protect against urinary incontinence and particularly detrusor overactivity following the procedure. |
| | | This large cross-country study showed that 35% of the 17,080 women analysed reported having urinary incontinence (UI). |
| | Hormonal manipulation is a well established treatment for prostate cancer. However, long-term treatment can be associated with troublesome side-effects. Recently, interest has turned to the possible adverse effects hormonal therapy may have on cognitive function. |
| | Testosterone replacement therapy does not increase the risk of prostate cancer in men with prostatic intraepithelial neoplasia, according to a study in the December issue of The Journal of Urology.
|
| | Expression of hepsin, a serine protease, correlates with the aggressiveness of prostate cancer, according to a report published in the January issue of The Journal of Urology. Hepsin may therefore represent a potentially useful prognostic indicator.
A link between hepsin expression and prostate cancer prognosis was first suggested in cDNA microarray studies. Until now, however, a quantitative analysis of the association had not been performed.
|
| | Ten-year follow-up of men treated with radiation for prostate cancer demonstrates significantly poorer survival than 5-year follow-up, according to a new study. Among a cohort of 205 men with T1-T2 prostate tumors, overall survival was 78% at 5 years and 53% at 10 years.
|
| | Measuring serum p53 antibody titers along with prostate specific antigen (PSA) levels appears to be a sensitive way to identify prostate cancer in patients with negative results on a digital rectal examination (DRE), investigators in Japan report. Such an assay may therefore assist physicians in deciding when a prostate biopsy is necessary.
|
| | | This article looks at three trials that are being performed at present in conjunction with the Bristol Urology Team. |
| | | The currently available tools for diagnosis and screening in prostate cancer lack accuracy. The most widely used diagnostic bloods test (PSA) and imaging test for bone metastases (bone scan) both lack sensitivity and specificity. |
|
|
|
|
